Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2017

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers

Delphine Hequet
  • Fonction : Auteur
Coraline Dubot
Paul Cottu
Cyril Huchon
  • Fonction : Auteur
Sonia Zilberman
  • Fonction : Auteur
Helene Berseneff
  • Fonction : Auteur
Aurélie Roulot
  • Fonction : Auteur
Anne Salomon
  • Fonction : Auteur
Nadeem Ghali
  • Fonction : Auteur
Pascale Morel
  • Fonction : Auteur
Qianyi Li
  • Fonction : Auteur
John Hornberger
  • Fonction : Auteur
Roman Rouzier
Daniele Santini
  • Fonction : Auteur
  • PersonId : 911283

Résumé

The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results.

Domaines

Cancer

Dates et versions

hal-01675231 , version 1 (04-01-2018)

Identifiants

Citer

Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, et al.. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers. PLoS ONE, 2017, 12 (10), pp.e0185753. ⟨10.1371/journal.pone.0185753⟩. ⟨hal-01675231⟩
121 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More